Feed THMO
Summary
32 / 100 · Bulios Score
Valuation 100Growth 15Profitability 6Quality 15Debt 1Stability 56
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 1.0% a year over the last 3 years.
- It missed profit estimates 8 times in the last 8 quarters.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
2019202020212022202320252026
Diluted EPS (USD)
2019202020212022202320252026
- Analyst estimate
Revenue fell by 1.0% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Cash and short-term investments $1.18M
Debt $6.93M
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2023By product
- Device Revenue 71%
- Service 19%
- Exclusivity Fee 8.1%
- Clinical Revenue 1.4%
By region
- UNITED STATES 63%
- CHINA 19%
- All Other Countries 7.6%
- VIET NAM 4.9%
- KOREA, REPUBLIC OF 3.1%
- Other 2.1%
Device Revenue brings in 71% of revenue. Exclusivity Fee grew fastest, by 69% a year.
Segments in detail